S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.39 (+2.34%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.39 (+2.34%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.39 (+2.34%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.39 (+2.34%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

$37.17
-3.44 (-8.47 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$36.86
Now: $37.17
$41.06
50-Day Range
$35.40
MA: $38.77
$42.74
52-Week Range
$18.07
Now: $37.17
$46.50
Volume7,949 shs
Average Volume82,772 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.92 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$1.19 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$37.17
-3.44 (-8.47 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by Coronavirus?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has increased by 43.3% and is now trading at $37.17.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for Odonate Therapeutics
.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics
.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) released its earnings results on Thursday, July, 30th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history
.

What price target have analysts set for ODT?

1 brokerages have issued twelve-month price objectives for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' share price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 30.1%.
View analysts' price targets for Odonate Therapeutics
.

Has Odonate Therapeutics been receiving favorable news coverage?

Headlines about ODT stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Odonate Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Odonate Therapeutics
.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 849,400 shares, an increase of 11.1% from the July 15th total of 764,300 shares. Based on an average daily volume of 78,000 shares, the days-to-cover ratio is presently 10.9 days. Approximately 2.9% of the shares of the company are sold short.
View Odonate Therapeutics' Short Interest
.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.17%), Assenagon Asset Management S.A. (0.16%), California Public Employees Retirement System (0.09%), Swiss National Bank (0.09%), Bessemer Group Inc. (0.06%) and State of Wisconsin Investment Board (0.05%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics
.

Which major investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, State of Wisconsin Investment Board, and UBS Group AG.
View insider buying and selling activity for Odonate Therapeutics
.

Which major investors are buying Odonate Therapeutics stock?

ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bessemer Group Inc., SG Americas Securities LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., New York State Common Retirement Fund, and Swiss National Bank. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics
.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $37.17.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $1.19 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.